OPINION Inherited and acquired disorders of magnesium homeostasis
INTRODUCTION
Magnesium (Mg 2þ ) is a frequently neglected electrolyte despite being the second most abundant intracellular cation [1] . Mg 2þ plays an important role in human physiology: it functions in over 600 enzymes as a cofactor, is crucial for nerve conduction and cardiac contractility, enhances resistance of DNA and RNA against oxidative stress by stabilizing their tertiary structure, cell cycle control and cell proliferation depend on Mg , and ATP has to bind Mg 2þ to be biologically active [2 && ]. Nevertheless, general practitioners frequently do not evaluate serum Mg 2þ [3, 4] . Hypermagnesemia occurs usually in preeclamptic women after Mg 2þ therapy and in patients with end-stage renal disease (ESRD). Elevated Mg 2þ concentrations cause muscle weakness, fatigue, and somnolence. Hypomagnesemia is more common and occurs in up to 15% of the general population [5] . Mild-to-moderate hypomagnesemia frequently does not cause symptoms, if more significant muscle spasms, arrhythmia, and seizures occur. Increasing evidence points to chronic hypomagnesemia as a risk factor for developing hypertension, type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, and cancer [6-9, undergoes reabsorption in a paracellular fashion, in between epithelial cells [17, 18] (Fig. 1 ). This allows for reabsorption of large amounts of Mg 2þ as this mode of reabsorption is nonsaturable [18] (Fig. 1a) .
Mg
2þ reabsorption in the cecum and colon occurs in a transcellular fashion via apical Mg 2þ channels transient receptor potential melastatin 6 (TRPM6) and TRPM7, which in contrast to paracellular transport is saturable ( Fig. 1a and b (Fig. 1c) . The main location for renal Mg 2þ reabsorption with 65-75% is the thick ascending limb of Henle (TAL). Here, Mg 2þ transport occurs in a paracellular mode [20] (Fig. 1c) . In the TAL, the major driving force for Mg 2þ reabsorption is the lumen-positive transepithelial potential difference. The fine tuning of renal Mg 2þ reabsorption occurs in the distal convoluted tubule (DCT) via apical TRPM6 and TRPM7 channels [21] (Fig. 1d) . Here, the negative membrane potential is a prerequisite for Mg 2þ reabsorption [22, 23] . As in the gut, it is unclear how Mg 2þ is exported on the basolateral side. Hypomagnesemias are because of medication side-effects (Table 1) , insufficient dietary Mg 2þ intake, or rare inherited renal defects, which are divided in hypercalciuric, Gitelman-like, and other hypomagnesemias (Table 2) .
HYPERCALCIURIC HYPOMAGNESEMIAS
These disorders share that the gene defect impairs paracellular Mg 2þ and Ca 2þ reabsorption in the TAL by disrupting the lumen-positive transepithelial potential difference and thereby cause hypercalciuria and hypomagnesemia.
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis
Symptoms in familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) include hypomagnesemia and hypocalcemia because of urinary Ca 2þ and Mg 2þ losses, nephrocalcinosis and, in some patients, eye involvement [42] [43] [44] . Infrequent symptoms are dRTA, hypocitraturia, nephrolithiasis, hyperuricemia, recurrent urinary tract infections, polyuria, and failure to thrive [45, 46] . Neurological symptoms because of hypomagnesemia are rare. Although patients grow relatively well tooth enamel defects can occur [47 & ,48] . In the teens to twenties, patients can develop chronic kidney disease and may require renal replacement therapy [45] . Recessive mutations in Claudin-16 (CLDN16) were published [49] . A genotype-phenotype correlation for CLDN16 mutations was published with earlier onset of ESRD with two loss-of-function mutations [45] . Patients with FHHNC and ocular involvement were found to have mutations in a related gene called Claudin-19 (CLDN19) [50] . Both proteins are strongly expressed in renal tissue, specifically in the TAL [49, 50, 51 && ]. Claudin-19 is also found in ocular tissue [50] . Claudin-16 and 19 both colocalize to tight junctions in the TAL and the DCT [49, 50] . Tight junctions are protein complexes in between epithelial cells, which determine the permeability of the epithelial barrier [51 && ]. Both proteins interact with each other and form heterodimers [52, 53] . Initially, it was thought that CLDN16 mutations would impair tubular Ca  2þ and  Mg  2þ reabsorption by disturbing a Ca  2þ and Mg   2þ selective channel [49] . However, the mechanism contributing to hypomagnesemia and hypercalciuria turned out to be more complex (Fig. 2a) . The lumen-positive potential difference, which is the major driving force for paracellular Ca 2þ and Mg 2þ reabsorption, is created by two different mechanisms: secretion of K þ via renal outer medullary potassium channel (ROMK), which is driven by the reabsorption of Na þ , K þ , and Cl À via the sodiumpotassium-chloride cotransporter (NKCC2) in the TAL, contributes to the lumen-positive potential. The second component of the lumen-positive potential is called the dilution potential and is explained in detail in Fig. 2a . Mutations in CLDN16 and 19 affect the creation of the dilution potential and result in a less lumen-positive potential [52] .
It remains unclear why FHHNC patients develop ESRD. Japanese cattle lacking Cldn16 developed
KEY POINTS
Mild-to-moderate chronic hypomagnesemia is a common problem in up to 15% of the general population but symptoms are usually absent or mild.
Because hypomagnesemia is associated with multiple common human disorders (e.g., hypertension, type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, and cancer), this electrolyte deserves better monitoring. tubulointerstitial nephritis with hypocalcemia but no hypomagnesemia [54, 55] . Immature tubular epithelial cells with loss of polarization and renal tubular dysplasia raise concern for a developmental defect. Cldn16 knockout mice displayed hypercalciuria and hypomagnesemia but no renal impairment [56] . Cldn19 knockout mice show disorganized tight junctions in Schwann cells, abnormal behavior, and neuropathy but no ocular or renal phenotype [57] . At this point, it is thought that hypercalciuria and nephrocalcinosis contribute to the development of ESRD. Hydrochlorothiazide treatment reduces hypercalciuria but had no effect on slowing down ESRD progression [58] .
Autosomal dominant hypocalcemia
Autosomal dominant hypocalcemia (ADH) is characterized by hypocalcemia, hypercalciuria, kidney stones, normal to inappropriately low PTH levels, and about 50% of all ADH patients have hypomagnesemia resulting in seizures and carpopedal spasms [59, 60] . ADH is caused by gainof-function mutations in the calcium-sensing receptor (CaSR) [61] . In the TAL, the CaSR is expressed at the basolateral membrane [62] ( Fig. 2b) . CASR mutations result in a higher sensitivity of the CaSR contributing to a higher receptor response despite physiological extracellular Ca 2þ concentrations, mimicking hypercalcemia [59] . Subsequently, PTH is suppressed and renal Ca 2þ
and Mg 2þ absorption is impaired [62, 63] . Patients with severe gain-of-function mutations in CaSR can develop Bartter syndrome (type V) [64] . Here, gainof function CASR mutations result in impaired NKCC2 and ROMK function. Different mechanisms of how CaSR activation contributes to urinary Na þ , K þ and Cl -losses are discussed ( Fig. 2b ) [62, 65, 66] . All these possibilities decrease the lumen-positive potential. Adapted with permission [19] . DCT, distal convoluted tubule; TAL, thick ascending limb; TRPM, transient receptor potential melastatin.
Recent studies outlined a novel, intricate mechanism how CaSR activation results in renal Ca 2þ and Mg 2þ wasting involving the calcineurin signaling pathway, nuclear factor of activated T-cells, specific microRNAs (miRNAs), and Claudin-14 ( Fig. 2b ) [67, 68 && ]. CASR stimulation enhances Claudin-14 expression, a negative regulator of Claudin-16 and 19. This diminishes the lumen-positive potential and contributes to urinary Ca 2þ and Mg 2þ losses. Downregulation of Claudin-14 and upregulation of Claudin-16 was confirmed in a Casr -/-mouse model [69] .
Classical Bartter syndrome
The features of classical Bartter syndrome (or Bartter syndrome type III) are polyuria, renal salt wasting, concentration defect, hypokalemic metabolic alkalosis, and hypercalciuria [70] . Later in life, patients can develop a Gitelman-like phenotype with hypocalciuria and hypomagnesemia [71, 72] . Classical Bartter syndrome is caused by recessive mutations in the CLCNKB gene, which encodes the basolateral chloride channel CLC-Kb (Fig. 2c) [73, 74] . Another form of antenatal Bartter syndrome (Bartter syndrome with deafness, or Bartter syndrome type IV) is because of recessive mutations in the BSND gene. BSND encodes the protein Barttin, which is a subunit of the CLC-Kb channel (Fig. 2c) [75] . This form of Bartter syndrome can also result in hypomagnesemia but may initially not display hypercalciuria and is therefore typically included in the Gitelmanlike forms of hypomagnesemia (Table 2) 
Mutations in CLCNKB and BSND disturb the intracellular Cl À regulation. This affects apical sodium-chloride co-transporter (NCC) and NKCC2 function, which subsequently interferes with the generation of the lumen-positive potential and may so disturb tubular Mg 2þ absorption [77, 78] .
GITELMAN-LIKE HYPOMAGNESEMIAS
Mg 2þ reabsorption in the DCT depends critically on the negative membrane potential. In this group, mutated proteins are involved in Na þ , K þ , or Cl À transport in the DCT, thereby disturbing the negative membrane potential. All disorders in this group result in hypocalciuria, volume contraction, hypotension, and activation of the renin-angiotensin system, which then drives K þ and H þ secretion, thus contributing to hypokalemia and metabolic alkalosis ( Table 2 ).
Gitelman syndrome
Gitelman syndrome is one of the most common tubulopathies with a prevalence of 1 : 40 000 [79] . Gitelman syndrome is characterized by hypokalemic alkalosis, hypocalciuria, and hypomagnesemia [80] . Symptoms include muscle weakness, fatigue, salt craving, thirst, nocturia, and carpopedal spasms. Clinical presentation is heterogenous ranging from asymptomatic to severe impairment of quality of life [81] . Recessive mutations were published in the SLC12A3 gene, which encodes the Na-Cl cotransporter NCC [82] . In up to 40% of patients, the second mutation cannot be detected possibly because of deep intronic location or large genomic rearrangements [83] [84] [85] . A Ncc knockout mouse model confirmed the human Gitelman syndrome phenotype with hypomagnesemia and hypocalciuria but lacked volume contraction and metabolic alkalosis [86, 87] . Ncc mutant mice displayed hypotension, volume contraction, metabolic alkalosis, and urinary Mg 2þ wasting [88] . Hypocalciuria and hypomagnesemia in Gitelman syndrome are thought to be the result of compensatory paracellular volume, Na þ and Ca 2þ reabsorption in the PT because of volume contraction [28, 87] . Regarding hypomagnesemia, different hypotheses were proposed, including K þ depletion, dysfunctional Mg 2þ absorption, atrophy of the DCT, and renal Mg 2þ wasting. Ncc À/À mice and thiazide treatment in wild-type mice displayed urinary Mg 2þ wasting because of less apical Trpm6 expression [28] . Tubulointerstitial nephritis [26] Diuretics (e.g., furosemide, thiazide)
# lumen positive potential difference in TAL blocking Na þ reabsorption in DCT affects membrane potential [27, 28] Platinum derivatives (e.g., cisplatin, carboplatin)
Necrotic nephropathy [29] PT and DCT injury [30, Epilepsy, ataxia, sensorineural deafness, and salt loosing tubulopathy syndrome EAST is an abbreviation for epilepsy, ataxia, sensorineural deafness, and salt loosing tubulopathy [89] . These patients present in early infancy with seizures, speech and motor delay, hearing impairments, and cerebellar symptoms such as ataxia, tremor, and dysdiadochokinesia [90] . Hypokalemic metabolic alkalosis, hypocalciuria, and hypomagnesemia develop during the disease course [91] . Recessive mutations in the basolateral, inwardly rectifying K þ channel Kir4.1 were identified [89, 92] . Consistent with the disease phenotype, Kir4.1 expression was found in the brain, stria vascularis of the inner ear, and DCT. Kir4.1 À/À mice displayed a phenotype similar to humans [89] . Kir4.1 forms heteromeric complexes with another K þ channel called Kir5.1 [93] . The basolateral Kir4.1/5.1 complex works together with the basolateral Na þ /K þ -ATPase by recycling K þ ions that entered the cell in exchange for extruding Na þ ions (Fig. 3a) [92,94 & ]. The distribution of extracellular and intracellular K þ is crucial for the generation of the negative membrane potential. The neurological phenotype is because of depolarization of neurons thus lowering the threshold for seizures [92] .
Isolated dominant hypomagnesemia
Isolated dominant hypomagnesemia (IDH) is characterized by hypocalciuria and hypomagnesemia but lacks hypokalemic metabolic alkalosis, salt wasting or renin-angiotensin systemstimulation. [95, 96] . FXYD2 encodes the g subunit of the Na (Fig. 3b) . FXYD2 enhances ATP and decreases Na þ affinity in a tissue-specific manner [97, 98] . Only one mutation (Gly to Arg at position 41) has been identified, which has a dominant negative effect resulting in incorrect trafficking and perinuclear accumulation of the mutant protein [95,99 & ]. Lack of FXYD2 in humans or mice does not cause Mg 2þ abnormalities. The mechanism how FXYD2 mutations cause Mg 2þ dysregulation remains unclear.
A second gene contributing to IDH was identified with the KCNA1 gene, which encodes the apical voltage-gated channel Kv1.1 [96] . Patients display muscle cramps, tetany, tremors, and muscle weakness. Urinary Mg 2þ wasting but no abnormalities regarding Ca 2þ were found. Ataxia and myokymia, an involuntary form of localized muscle trembling, were found in all affected patients. Interestingly, KCNA1 mutations were previously described in other patients with ataxia and myokymia [100] . However, only the N255D (Asn to Asp at position 255) mutation caused hypomagnesemia [96] . Kv1.1 colocalizes with TRPM6 in the DCT but does not regulate TRPM6. The Kv1.1 channel forms tetramers and coexpression of mutant and wild-type KV1.1 results in a dominant negative effect of the mutant Kv1.1. As channel trafficking is preserved, probably gating of the channel pore is affected resulting in diminished negative membrane potential (Fig. 3b) .
HNF1B nephropathy
Mutations in HNF1B result in a spectrum of symptoms, including maturity-onset diabetes of the young Different hypotheses consider that a dysfunctional g subunit of the Na þ /K þ -ATPase may result in reduced intracellular K þ concentration (which may depolarize the apical membrane and so impair Mg 2þ reabsorption), altered intracellular Na þ concentration (which could affect a putative basolateral Mg 2þ -Na þ exchanger), the g subunit could also be important for the Mg 2þ -Na þ exchanger, and a defective Na þ /K þ -ATPase disturbs potentially cellular energy metabolism and may result in a higher risk of apoptosis. For IDH because of KCNA1 mutations: the negative membrane voltage, which is maintained by an apical K þ efflux via Kv1.1, is crucial as Mg 2þ uptake from the ultrafiltrate via the TRPM6 channel is driven by a favorable negative membrane voltage. (c) HNF1B and PCBD1 form a heteromeric complex and stimulate FXYD2 transcription, which encodes a subunit of the Na [106] . Mutations in HNF1B can be inherited in an autosomal dominant fashion or occur de novo. HNF1B encodes the transcription factor hepatocyte nuclear factor 1b, a member of the homeodomain-containing superfamily, which is crucial for renal and pancreatic development. HNF1B regulates other proteins, which are involved in renal Mg 2þ absorption such as FXYD2 [106] . Several HNF1B binding sites were identified in the FXYD2 promoter and HNF1B mutations impair FXYD2 transcription [107] .
Transient neonatal hyperphenylalaninemia and primapterinuria
Transient neonatal hyperphenylalaninemia and primapterinuria is a benign neonatal syndrome without long-term sequela [108] . However, three adults with hypomagnesemia, renal Mg 2þ losses, and MODY were found to have recessive mutations in the gene PCBD1, which usually causes the transient metabolic disease [109] . The encoded protein pterin-4a carbinolamine dehydratase forms a heterotetrameric complex by physically interacting with HNF1B and is a crucial dimerization factor [109] . Defective dimerization because of mutant PCBD1 results in proteolytic instability of the PCBD1-HNF1B complex and subsequently impaired HNF1B-mediated stimulation of FXYD2 promoter activity (Fig. 3c) .
OTHER HYPOMAGNESEMIA
This group includes different inherited diseases which may not fit in one of the above listed groups (Table 2) .
Isolated recessive hypomagnesemia
Isolated recessive hypomagnesemia is caused by recessive mutations in the EGF gene [38] . The affected individuals developed seizures in infancy, developmental delay, hypomagnesemia because of renal Mg 2þ wasting, but no other electrolyte abnormality [110] . A homozygous mutation in the pro-EGF gene, encoding for the epidermal growth factor, was identified [38] . Pro-EGF is a type 1 transmembrane protein with 1207 amino acids, which is cleaved to the final EGF (53 amino acids length). The identified mutation is located in the cytosolic C-terminus within a sorting motif and results in impaired EGF secretion [38] . Wild-type EGF is secreted and binds to EGF receptor at the basolateral membrane of the DCT, thereby activating a tyrosine kinase, which stimulates TRPM6 [38] (Fig. 4) . The significance of EGF as an autocrine magnesiotropic hormone was confirmed by the chimeric human/ mouse anti-EGF antibody cetuximab in chemotherapy as patients treated with cetuximab develop hypomagnesemia [111] .
Hypomagnesemia with secondary hypocalcemia
Patients with this rare condition present with generalized seizures in early infancy, severely low serum Mg 2þ (approximately 0.2 mmol/l), and hypocalcemia [112] . Perfusion studies in humans indicated an intestinal and renal Mg 2þ leak [113] . The cause of hypocalcemia is poorly understood but it seems that low Mg 2þ impairs PTH secretion [114] . Consistent with this finding, hypomagnesemia with secondary hypocalcemia patients have inappropriately low PTH concentrations. The hypocalcemia does not respond to Ca 2þ or vitamin D supplements but only to Mg 2þ supplementation [115] . Recessive mutations in the gene encoding the TRPM6 channel, a member of the TRP family with a C-terminal kinase domain, were published [116, 117] . TRPM6 is expressed in the gut (e.g., duodenum, jejunum, colon) and the kidney (e.g., DCT) [118] . TRPM6 is homologous to TRPM7, another channel permeable to Ca 2þ and Mg 2þ . Both, TRPM6 and 7 form heteromers, interact and modify each other [119] . TRPM6 is regulated by multiple factors, including hypomagnesemia, estradiol, and calcineurin inhibitors [35, 120, 121] .
Hypomagnesemia with impaired brain development
Patients present with seizures, hypomagnesemia ($0.4-0.5 mmol/l), muscle weakness, vertigo, and headaches. Heterozygous and homozygous CNNM2 mutations were found in affected individuals but some mutation carriers remained asymptomatic [122] . CNNM2 encodes the transmembrane protein cyclin M2, which is expressed at the basolateral side of the TAL and DCT. Truncating and missense mutations were published, the latter impaired Mg 2þ sensitive current [122, 123] . The physiological function of CNNM2 remains unknown, but involves possibly a role as Mg 2þ transporter or Mg 2þ sensor [122, 124 & ].
Mitochondrial hypomagnesemia
Metabolic disease with hypercholesterolemia, and hypertension was found linked with hypomagnesemia in a large kindred [125] . Interestingly, only women were affected pointing to mitochondrial inheritance. Hypomagnesemia was associated with hypocalciuria indicating involvement of the DCT. A mutation in the mitochondrially encoded isoleucine tRNA gene was found. The mutation affects a thymidine residue adjacent to the anticodon triplet, which is extremely conserved and critical for codon-anticodon recognition. Interestingly, additional mitochondrial disorders have been identified causing hypomagnesemia also involving the TAL [126] [127] [128] . Both TAL and DCT have high energy requirements but the exact mechanism how mitochondrial disorders contribute to hypomagnesemia remains unclear.
CONCLUSION
Despite the identification of several genes with rare Mendelian disorders our understanding of renal Mg 2þ homeostasis remains very incomplete. Most of the inherited conditions alter the lumen-positive potential in the TAL or the negative membrane potential in the DCT and only few conditions affect directly a Mg 2þ channel. As most of the patients present with neurological symptoms practitioners need to be vigilant and neurologists should be educated about the nature of these conditions. Acknowledgements I would like to thank Dr Michel Baum and Dr Jyothsna Gattineni for their support with this review.
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